Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 11/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | SLC9A1 | P19634 | 2/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
| ▸ | ILK | Q13418 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19436028 | 0.86 | FFAR1 (0.44) | FFAR1SLC9A1 | |
| SCHEMBL19435966 | 0.86 | FFAR1 (0.43) | FFAR1HSD17B10SLC9A1CHEK1ILK | |
| SCHEMBL19436037 | 0.85 | FFAR1 (0.44) | FFAR1HSD17B10SLC9A1CHEK1ILK | |
| SCHEMBL19436265 | 0.84 | FFAR1 (0.44) | FFAR1HSD17B10SLC9A1CHEK1ILK | |
| SCHEMBL19435929 | 0.84 | FFAR1 (0.44) | FFAR1HSD17B10SLC9A1ILKPDK2 | |
| SCHEMBL19436248 | 0.82 | FFAR1 (0.47) | FFAR1HSD17B10SLC9A1ILK | |
| SCHEMBL19436124 | 0.81 | FFAR1 (0.47) | FFAR1HSD17B10SLC9A1PDK2 | |
| SCHEMBL19435905 | 0.80 | FFAR1 (0.47) | FFAR1HSD17B10SLC9A1CHEK1ILK | |
| SCHEMBL19436186 | 0.78 | FFAR1 (0.47) | FFAR1 | |
| SCHEMBL17669359 | 0.73 | FFAR1 (0.57) | FFAR1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10106553-B2 | Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV (BE) | 2018-10-23 | — | — | US | disclosed |
| WO-2017180571-A1 | SUBSTITUTED BENZOTHIOPHENYL DERIVATIVES AS GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2017-10-19 | — | — | WO | disclosed |
| US-20170291908-A1 | SUBSTITUTED BENZOTHIOPHENYL DERIVATIVES AS GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2017-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170291908-A1 | SUBSTITUTED BENZOTHIOPHENYL DERIVATIVES AS GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | GPR119, GPR65, GPR52 | FFAR1 11/4885HSD17B10 1077/4885SLC9A1 2894/4885 |
| US-10106553-B2 | Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes | GPR119, GPR65, GPR52 | FFAR1 11/4885HSD17B10 1077/4885SLC9A1 2894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.